Pharmaceutical approaches for optimizing oral anti-inflammatory delivery systems

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2011, Pages 154-165

  Lopes, C M ^a,b   Oliveira, R ^b   Silva, A C ^a,c  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anti inflammatory drugs; Coated systems; Colloidal carriers; Colon systems; Gastroretentive systems; Matrix systems; Microparticles; Osmotic systems; Prodrugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AQUASOME; AZO COMPOUND; BUDESONIDE; CARBOMER; CHONDROITIN SULFATE; CYCLODEXTRIN; DENDRIMER; DEXAMETHASONE; DICLOFENAC; DRUG CARRIER; FLURBIPROFEN; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; LIPOSOME; LORNOXICAM; MESALAZINE; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOTIC AGENT; POLYSACCHARIDE; POVIDONE; PREDNISOLONE; PRODRUG; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COLLOID; COLON; COLON CANCER; CONTROLLED DRUG RELEASE; DELAYED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RETENTION; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; HYDROGEL; OSMOSIS; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; SYSTEMIC DISEASE; ULCERATIVE COLITIS;

EID: 79960600852     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011109030154     Document Type: Review

References (160)

1. Rele, S.M.; Cui, W., Wang, L.; Hou, S.; Barr-Zarse G.; Tatton, D.; Gnanou, Y.; Esko, J.D.; Chaikof, E.L. Dendrimer-like PEO glycopolymers exhibit anti-inflammatory properties. J Am Chem Soc, 2005, 127(29), 10132-10133.
2. Na, M.; Yiyun, C.; Tongwen, X.; Yang, D.; Xiaomin, W.; Zhenwei, L.; Zhichao, C.; Guanyi, C.; Yunyu, S.; Longping, W. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur J Med Chem, 2006, 41(5), 670-674.
3. [http://www.reactivereports.com/68/68_2.html. (Accessed August, 2010).
4. Al Malyan, M.; Becchi, C.; Nikkola, L.; Viitanen, P.; Boncinelli, S.; Chiellini, F.; Ashammakhi, N. Polymer-based biodegradable drug delivery systems in pain management. J Craniofac Surg, 2006, 17(2), 302-313.
5. Longer, M. A.; Robinson, J.R. Sustain release Drug Delivery System, 18th ed.; Mark Easton: New York, 1990.
6. Avachat, A.; Kotwal, V. Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate. AAPS PharmSciTech, 2007, 8(4), E88.
7. Reza, M.S.; Quadir, M.A.; Haider, S.S. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharm Sci, 2003, 6(2), 282-291.
8. [Rani, M.; Mishra, B. Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS PharmSciTech, 2004, 5(4): article 71.
9. Yeole, P.G.; Galgatle, U.C.; Babla, I.B.; Nakhat, P.D. Design and evaluation of xanthan gum-based sustained release matrix tablets of diclofenac sodium. Indian J Pharm Sci, 2006, 68, 185-189.
10. Sarfraz, M.K.; Rehman, N.U.; Mohsin, S. Naproxen release from sustained release matrix system and effect of cellulose derivatives. Pak J Pharm Sci, 2006, 19(3), 251-255.
11. Sarfraz, M.K.; Rehman, N.; Ahmed, S.; Asharaf, M.; Mohsin, S. Ethyl cellulose-based solid matrix system for sustaining release of naproxen. Pak J Biol Sci, 2007, 10(4), 668-672.
12. Kulkarni, R.V.; Shah, A.; Boppana, R. Development and evaluation of xyloglucan matrix tablets containing naproxen. Asian J Pharm, 2008, 2, 102-105.
13. Amaral, M.H.; Lobo, J.M.; Ferreira, D.C. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets. AAPS PharmSciTech, 2001, 2(2), E6.
14. Saeio, K.; Pongpaibul, Y.; Viernstein, H.; Okonogi, S. Factors influencing drug dissolution characteristics from hydrophilic polymer matrix tablet. J Sci Pharm, 2007, 75, 147-163.
15. Mesnukul, A.; Yodkhum, K.; Phaechamud, T. Solid dispersion matrix tablet comprising indomethacin-PEG-HPMC fabricated with fusion and mold technique. Indian J Pharm Sci, 2009, 71, 413-420.
16. Mesnukul, A.; Yodkhum, K.; Mahadlek, J.; Phaechamud, T. Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique. Indian J Pharm Sci, 2010, 72, 92-100.
17. Roy, P.; Shahiwala, A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Control Release, 2009, 134(2), 74-80.
18. Zaghloul, A.A.; Vaithiyalingam, S.R.; Faltinek, J.; Reddy, I.K.; Khan, M.A. Response surface methodology to obtain naproxen controlled release tablets from its microspheres with Eudragit L100-55. J Microencapsul, 2001, 18(5), 651-662.
19. Ivic, B.; Ibric, S.; Betz, G.; Gjuric, Z. Evaluation of diclofenac sodium release from matrix pellets compressed into MUPS tablets. Yakugaku Zasshi, 2009, 129(11), 1375-1384.
20. Lopes, C.M.; Sousa Lobo, J.M.; Costa, P.; Pinto, J.F. Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release. Drug Dev Ind Pharm, 2006, 32(1), 95-106.
21. Lutchman, D.; Dangor, C. M.; Perumal, D. Formulation of ratemodulating pellets for the release of ibuprofen: an extrusionspheronization process. J Microencapsul, 2005, 22(6), 643-659.
22. De Brabander, C.; Vervaet, C.; Bortel, L. V.; Remon, J. P. Bioavailability of ibuprofen from hot-melt extruded mini-matrices. Int J Pharm, 2004, 271(1-2), 77-84.
23. Sevgi, F.; Kaynarsoy, B.; Ertan, G. An anti-inflammatory drug (mefenamic acid) incorporated in biodegradable alginate beads:development and optimization of the process using factorial design. Pharm Dev Technol, 2008, 13(1), 5-13.
24. Staniforth, J.N.; Baichwal, A.R. TIMERx: novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opin Drug Deliv, 2005, 2(3), 587-595.
25. Dalton, J.T.; Straughn, D.A.; Dickason, D.A.; Grandolfi, G.P. Predictive ability of level A in vitro-in vivo correlation for ringcap controlled-release acetaminophen tablets. Pharm Res, 2001, 18(12), 1729-1734.
26. Conte, U.; Maggi, L.; Colombo, P.; La Manna, A. Multilayered hydrophilic matrices as constant release devices (GeomatrixTM systems). J Control Release, 1993, 26, 39-47.
27. El-Nabarawi, M.A. Modulation of Tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane. Chem Pharm Bull (Tokyo), 2005, 53(9), 1083-1087.
28. Zerbe, H.G.; Krumme, M. Smartrix system: design characteristics and release properties of a novel erosion-controlled oral delivery system; In: Modified-Release Drug Delivery Technology; M.J. Rathbone, J. Hadgraft, and M.S. Roberts, Eds.; Marcel Dekker: New York, 2003; pp. 35-48.
29. Kim, C.J. Controlled release from triple layer, donut-shaped tablets with enteric polymers. AAPS PharmSciTech, 2005, 6(3), E429-36.
30. Maggi, L.; Machiste, E.O.; Torre, M.L.; Conte, U. Formulation of biphasic release tablets containing slightly soluble drugs. Eur J Pharm Biopharm, 1999, 48(1), 37-42.
31. Lopes, C.M.; Lobo, J.S.; Pinto, J.F.; Costa, P.C. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech, 2007, 8(3), E76.
32. Lopes, C.M., Sousa Lobo, J.M.; Pinto, J.F.; Costa, P.C. Compressed mini-tablets as a biphasic delivery system. Int J Pharm, 2006, 323(1-2), 93-100.
33. Hamza Yel, S.; Aburahma, M.H. Design and in vitro evaluation of novel sustained-release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers. Pharm Dev Technol, 2010, 15(2), 139-153.
34. Hamza Yel, S.; Aburahma, M.H. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination. AAPS PharmSciTech, 2009, 10(4), 1357-1367.
35. Aburahma, M.H.; Hamza, Y.E. Novel sustained-release fastdisintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads. Pharm Dev Technol, 2010.
36. Hashmat, D.; Shoaib, M.A.; Mehmood, Z.A.; Bushra, R.; Yousuf, R.I.; Lakhani, F. Development of enteric coated flurbiprofen tablets using Opadry/Acryl-Eze system--a technical note. AAPS PharmSciTech, 2008, 9(1), 116-121.
37. Missaghi, S.; Fassihi, R. A novel approach in the assessment of polymeric film formation and film adhesion on different pharmaceutical solid substrates. AAPS PharmSciTech, 2004, 5(2), E29.
38. Tang, E.S.K.; Chan, L.W.; Paul, W.S. Coating of multiparticulates for sustained release. Am J Drug Del, 2005, 3, 17-28.
39. Frohoff-Hulsmann, M.A.; Lippold, B.C.; McGinity, J.W. Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and hydroxypropyl methyl-cellulose as coating material for diffusion pellets II: properties of sprayed films. Eur J Pharm Biopharm, 1999, 48(1), 67-75.
40. Okarter, T.U.; Singla, K. The effects of plasticizers on the release of metoprolol tartrate from granules coated with a polymethacrylate film. Drug Dev Ind Pharm, 2000, 26(3), 323-329.
41. Shao, Z.J.; Moralesi, L.; Diaz, S.; Muhammadi, N.A. Drug release from Kollicoat SR 30D-coated nonpareil beads: evaluation of coating level, plasticizer type, and curing condition. AAPS PharmSciTech, 2002, 3(2), E15.
42. Okor, R.S.; Eichie, F.E.; Uhumwangho, M.V.; Aka-Aha, A.P. Effect of protective coating of aspirin tablets with acrylatemethacrylate copolymers on tablet disintegration times and dissolution rates. Indian J Pharm Sci, 2007, 69, 591-594.
43. Abbaspour, M.R.; Sadeghi, F.; Afrasiabi Garekani, H. Design and study of ibuprofen disintegrating sustained-release tablets comprising coated pellets. Eur J Pharm Biopharm, 2008, 68(3), 747-759.
44. Rohera, B.D.; Parikh, N.H. Influence of plasticizer type and coat level on Surelease film properties. Pharm Dev Technol, 2002, 7(4), 407-420.
45. Sadeghi, F.; Ford, J.L.; Rajabi-Siahboomi, A. The influence of drug type on the release profiles from Surelease-coated pellets. Int J Pharm, 2003, 254(2), 123-135.
46. Kibria, G.; Roni, M.A.; Absar, M.S.; Ul-Jalil, R. Effect of plasticizer on release kinetics of diclofenac sodium pellets coated with Eudragit RS 30 D. AAPS PharmSciTech, 2008, 9(4), 1240-1246.
47. Kramar, A.; Turk, S.; Vrecer, F. Statistical optimisation of diclofenac sustained release pellets coated with polymethacrylic films. Int J Pharm, 2003, 256(1-2), 43-52.
48. Krejcova, K.; Rabisková, M.; Vetchy, D.; Tomásek, V.; Prokopová, A. The effect of polymeric dispersion type on the release of diclofenac sodium from coated pellets. Ceska Slov. Farm, 2007, 56(4), 190-199.
49. Kibria, G.; Ul-Jalil, R. The effect of the ratio of two acrylic polymers on the in vitro release kinetics of ketoprofen from pellets prepared by extrusion and spheronisation technique. Pak J Pharm Sci, 2008, 21(2), 92-97.
50. Yamada, T.; Onishi, H.; Machida, Y. Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose. J Control Release, 2001, 75(3), 271-282.
51. ® Technology). http://www.elandrugtechnologies.com/nav/30/ (Accessed August, 2010).
52. Philip, A.K. Osmotically regulated flow of flurbiprofen through in situ formed asymmetric membrane capsule. Curr Drug Deliv, 2008, 5(2), 127-132.
53. Philip, A.K.; Pathak, K. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility. AAPS PharmSciTech, 2006, 7(3), 56.
54. Philip, A.K.; Pathak, K. Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled, and level A IVIVC for poorly water-soluble drug. Drug Dev Ind Pharm, 2008, 34(7), 735-743.
55. Philip, A.; Pathak, K. In situ-formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug. PDA J Pharm Sci Technol, 2007, 61(1), 24-36.
56. Yakubu, R.; Peh, K.K.; Tan, Y.T. Design of a 24-hour controlled porosity osmotic pump system containing PVP: formulation variables. Drug Dev Ind Pharm, 2009, 35(12), 1430-1438.
57. Lu, E.X.; Jiang, Z.Q.; Zhang, Q.Z.; Jiang, X.G. A water-insoluble drug monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent. J Control Release, 2003, 92(3), 375-382.
58. Kumar, P.; Mishar, B. Studies on elementary osmotic pump tablets of naproxen sodium. Acta Pharma Turcica, 2004, 46, 35-41.
59. Shokri, J.; Ahmadi, P.; Rashidi, P.; Shahsavari, M.; Rajabi-Siahboomi, A.; Nokhodchi, A. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm, 2008, 68(2), 289-297.
60. Sotthivirat, S.; Haslam, J.L.; Lee, P.I.; Rao, V.M.; Stella, V.J. Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutyletherbeta-cyclodextrin as both a solubilizing and osmotic agent. J Pharm Sci, 2009, 98(6), 1992-2000.
61. Ettmayer, P.; Amidon, G.L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J Med Chem, 2004, 47(10), 2393-2404.
62. Han, H.K.; Amidon, G.L. Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2000, 2(1), E6.
63. Dvir, E.; Friedman, J.E.; Lee, J.Y.; Koh, J.Y.; Younis, F.; Raz, S.; Shapiro; I.; Hoffman, A.; Dahan, A.; Rosenberg, G.; Angel, I.; Kozak, A.; Duvdevani, R. A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. J Pharmacol Exp Ther, 2006, 318(3), 1248-1256.
64. Dvir, E.; Elman, A.; Simmons, D.; Shapiro, I.; Dahan, A.; Hoffman, A.; Friedman; J.E.; Duvdevani, R. DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev, 2007, 13(2), 260-277.
65. Dahan, A., Duvdevani, R.; Dvir, E.; Elmann, A.; Hoffman, A. A novel mechanism for oral controlled release of drugs by continuousdegradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J Control Release, 2007, 119(1), 86-93.
66. Dahan, A.; Hoffman, A. Mode of administration-dependent brain uptake of indomethacin: sustained systemic input increases brain influx. Drug Metab Dispos, 2007, 35(2), 321-324.
67. Lanas, A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res Ther, 2008, 10(2), S4.
68. Nemmani, K.V.; Mali, S.V.; Borhade, N.; Pathan, A.R.; Karwa, M.; Pamidiboina, V.; Senthilkumar, S.P.; Gund, M.; Jain, A.K.; Mangu, M.; Dubash, N.P.; Desai, D.C.; Sharma, S.; Satyam, A. NO-NSAIDs: Gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs. Bioorg Med Chem Lett, 2009, 19(18), 5297-5301.
69. Abdellatif, K.R.; Chowdhury, M.A.; Dong, Y.; Das, D.; Yu, G.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett, 2009, 19(11), 3014-3018.
70. Varshosaz, J.; Emami, J.; Tavakoli, N.; Fassihi, A.; Minaiyan; M.; Ahmadi, F.; Dorkoosh, F. Synthesis and evaluation of dextranbudesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm, 2009, 365(1-2), 69-76.
71. Nahar, M.; Dutta, T.; Murugesan, S.; Asthama, A.; Mishra, D.; Rajkumar, V.; Tare, M.; Saraf, S.; Jain, N.K. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst, 2006, 23(4), 259-318.
72. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J.; Préat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release, 2006, 116(1), 1-27.
73. Bowman, K.; Leong, K.W. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine, 2006, 1(2), 117-128.
74. Singh, R.; Singh, S.; Lillard, J.W.Jr. Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci, 2008, 97(7), 2497-2523.
75. Lopes, C.M.; Martins-Lopes, P.; Souto, E.B. Nanoparticulate carriers (NPC) for oral pharmaceutics and nutraceutics. Pharmazie, 2010, 65(2), 75-82.
76. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 2001, 70(1-2), 1-20.
77. Tobio, M.; Sánchez, A.; Vila, A.; Soriano, I.I.; Evora, C.; Vila-Jato, J.L.; Alonso, M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces, 2000, 18(3-4), 315-323.
78. Bansal, S.S.; Joshi, A.; Bansal, A K. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging, 2007, 24(6), 441-451.
79. Sepassi, S.; Goodwin, D.J.; Drake, A.F.; Holland, S.; Leonard, G.; Martini, L.; Lawrence, M.J. Effect of polymer molecular weight on the production of drug nanoparticles. J Pharm Sci, 2007, 96(10), 2655-2666.
80. Graves, R.A.; Poola, D.; Moiseyev, R.; Bostanian, L.A.; Mandal, T.K. Encapsulation of indomethacin using coaxial ultrasonic atomization followed by solvent evaporation. Drug Dev Ind Pharm, 2008, 34(4), 419-426.
81. Bernardi, A.; Zilberstein, A.C.; Jager, F.; Campos, M.M.; Morrone, F.B.; Calixto, J.B.; Pohlmann, A.R.; Guterres, S.S.; Battastini, A.M. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol, 2009, 158(4), 1104-1111.
82. Helle, A., Hirsjarvi, S.; Peltonen, L.; Hirvonen, J.; Wiedmer, S.K.; Hyotylainen, T. Novel, dynamic on-line analytical separation system for dissolution of drugs from poly(lactic acid) nanoparticles. J Pharm Biomed Anal, 2009, 51(1), 125-130.
83. Ain-Ai, A.; Gupta, P.K. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound. Int J Pharm, 2008, 351(1-2), 282-288.
84. Lapresta-Fernandez, A.; Cywinski, P.J.; Moro, A.J.; Mohr, G.J. Fluorescent polyacrylamide nanoparticles for naproxen recognition. Anal Bioanal Chem, 2009, 395(6), 1821-1830.
85. Lai, F.; Sinico, C.; Ennas, G.; Marongiu, F.; Marongiu, G.; Fadda, A.M. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm, 2009, 373(1-2), 124-132.
86. Arias, J.L.; López-Viota, M.; Sáez-Fernández, E.; Ruiz, M.A. Formulation and physicochemical characterization of poly([var epsilon]-caprolactone) nanoparticles loaded with ftorafur and diclofenac sodium. Colloids Surf B: Biointerf, 2009, 75(1), 204-208.
87. Ambrus, R.; Kocbek, P.; Kirstl, J.; Sibanc, R.; Rajkó, R.; Szabó- Révesz, P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm, 2009, 381(2), 153-159.
88. Ravikumara, N.R.; Madhusudhan, B.; Nagaraj, T.S.; Hiremat, S.R.; Raina, G. Preparation and evaluation of nimesulide-loaded ethylcellulose and methylcellulose nanoparticles and microparticles for oral delivery. J Biomater Appl, 2009, 24(1), 47-64.
89. Zhang, Z.; Grijpma, D.W.; Feijen, J. Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J Control Release, 2006, 111(3), 263-270.
90. Ali, H.S.M.; York, P.; Blagden, N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm, 2009, 375(1-2), 107-113.
91. Friend, D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev, 2005, 57(2), 247-265.
92. Pertuit, D.; Moulari, B.; Betz, T.; Nadaradjane, A.; Neumann, D.; Ismaili, L.; Refouvelet, B.; Pellequer, Y.; Lamprecht, A. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release, 2007, 123(3), 211-218.
93. Laroui, H.; Dalmasso, G.; Nguyen, H.T.T.; Yan, Y.; Sitaraman, S.V.; Merlin, D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 2009, 138(3), 843-853.
94. Torchilin, V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res, 2007, 24(1), 1-16.
95. Lavasanifar, A.; Samuel, J.; Kwon, G.S. Poly(ethylene oxide)- block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev, 2002, 54(2), 169-190.
96. Singh, R.; Lillard, J.W.Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol, 2009, 86(3), 215-223.
97. Jiang, G.B.; Quan, D.; Liao, K.; Wang, H. Novel polymer micelles prepared from chitosan grafted hydrophobic palmitoyl groups for drug delivery. Mol Pharm, 2006, 3(2), 152-160.
98. Wei, H.; Zhang, X.Z.; Zhou, Y.; Cheng, S.X.; Zhuo, R.X. Selfassembled thermoresponsive micelles of poly(N-isopropylacrylamide-b-methyl methacrylate). Biomaterials, 2006, 27(9), 2028-2034.
99. Xia, W.; Chang, J.; Lin, J.; Zhu, J. The pH-controlled dual-drug release from mesoporous bioactive glass/polypeptide graft copolymer nanomicelle composites. Eur J Pharm Biopharm, 2008, 69(2), 546-552.
100. Müller, R.H.; Mehnert, W.; Lucks, J.S.; Schwarz, C.; zur Muhlen, A.; Weyhers, H.; Freitas, C.; Ruhl, D. Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 1995, 41, 62-69.
101. Mehnert, W.; Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001, 47, 165-196.
102. [Muller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 2002, 242(1-2),. 121-128.
103. Casadei, M.A.; Cerreto, F.; Cesa, S.; Giannuzzo, M.; Feeney, M.; Marianecci, C.; Paolicelli, P. Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations. Int J Pharm, 2006, 325(1-2), 140-146.
104. Silva, A.C.; Santos, D.; Ferreira, D.C.; Souto, E.B. Oral delivery of drugs by means of solid lipid nanoparticles. Minerva Biotecnologica, 2007, 19, 1-5.
105. Serpe, L.; Canaparo, R.; Daperno, M.; Sostegni, R.; Martinasso, G.; Muntoni, E.; Ippolito, L.; Vivenza, N.; Pera, A.; Eandi, M.; Gasco, M.R.; Zara, G.P. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci, 2010, 39(5), 428-436.
106. [Date, A.A.; Joshi, M.D.; Patravale, V.B. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev, 2007, 59(6), 505-521.
107. Oussoren, C.; Storm, G.; Crommelin, D.J.A.; Senior, J.H. Liposomes for local sustained drug release. In: Sustained-Release Injectable Products; M.R.J.H. Senior, Ed.; Interpharm Press: Denver, 2000; pp. 137-180.
108. Gregoriades, G.F.A.T.; Patel, H.M. Liposomes in drug delivery; Harwood Academic Publishers: Amesterdam, 1993.
109. Sharma, A.; Sharma, U. Liposomes in drug delivery: progress and limitations. Int J Pharm, 1997, 154(2), 123-140.
110. Walde, P.; Ichikawa, S. Enzymes inside lipid vesicles: preparation, reactivity and applications. Biomol Eng, 2001, 18(4), 143-177.
111. Davis, S.S. Coming of age of lipid-based drug delivery systems. Adv Drug Deliv Rev, 2004, 56(9), 1241-1242.
112. Katare, O.P.; Vyas, S.P.; Dixit, V.K. Proliposomes of indomethacin for oral administration. J Microencapsul, 1991, 8(1), 1-7.
113. Stozek, T. Bioavailability of indomethacin in liposomes. Acta Pol Pharm, 1992, 49(4), 21-26.
114. Deniz, A.; Sade, A.; Severcan, F.; Keskin, D.; Tezcaner, A.; Bamerjee, S. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics. Biosci Rep, 2010, 30(5), 365-373.
115. Clares, B.; Gallardo, V.; Medina, M.M.; Ruiz, M. A. Multilamellar liposomes of triamcinolone acetonide: preparation, stability, and characterization. J Liposome Res, 2009, 19(3), 197-206.
116. Park, K.; Yeo, Y. Microencapsulation Technology. In: Encyclopedia of Pharmaceutical Technology; Swarbrick, J., Ed.; Informa Healthcare: New York, 2007, 2315-2325.
117. Ravi Kumar, M.N. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci, 2000, 3(2), 234-258.
118. Constantin, M.; Fundueanu, G.; Bortolotti, F.; Cortesi, R.; Ascenzi, P.; Menegatti, E. A novel multicompartimental system based on aminated poly(vinyl alcohol) microspheres/succinoylated pullulan microspheres for oral delivery of anionic drugs. Int J Pharm, 2007, 330(1-2), 129-137.
119. Fonseca, L.S.; Silveira, R.P.; Deboni, A.M.; Benvenutti, E.V.; Costa, T.M.H.; Guterres, S.S.; Pohlmann, A.R. Nanocapsulexerogel microparticles containing sodium diclofenac: a new strategy to control the release of drugs. Int J Pharm, 2008, 358(1-2), 292-295.
120. Mladenovska, K.; Cruaud, O.; Richomme, P.; Belamie, E.; Raicki, R.S.; Venier-Julienne, M.C.; Popovski, E.; Benoit, J.P., Goracinoca, K. 5-ASA loaded chitosan-Ca-alginate microparticles: Preparation and physicochemical characterization. Int J Pharm, 2007, 345(1-2), 59-69.
121. Onishi, H.; Oosegi, T.; Machida, Y.; McGinity, J.W. Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres. Drug Dev Ind Pharm, 2007, 33(8), 848-854.
122. Rojas-Oviedo, I.; Salazar-López, R.A.; Reyes-Gasga, J.; Quirino-Barreda, C.T. Elaboration and structural analysis of aquasomes loaded with indomethacin. Eur J Pharm Sci, 2007, 32(3), 223-230.
123. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur Polymer J, 2003, 39(9), 1741-1771.
124. Cheng, Y.; Xu, Z.; Ma, M.; Xu, T. Dendrimers as drug carriers: Applications in different routes of drug administration. J Pharm Sci, 2008, 97(1), 123-143.
125. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. Synthesis, characterization and stability of dendrimer prodrugs. Int J Pharm, 2006, 308(1-2), 175-182.
126. Garg, R.; Gupta, G.D. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res, 2008, 7(3), 1055-1066.
127. Nayak, A.K.; Maji, R.; Das, B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res, 2010, 3(1), 2-10.
128. Bardonnet, P.L.; Faivre, V.; Pugh, W.J., Piffaretti, J.C.; Falson, F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release, 2006, 111(1-2), 1-18.
129. Basavaraj, B.V., Deveswaran, R.; Bharath, S.; Sindhu Abraham; Sharon Furtado; Madhavan, V. Hollow microspheres of diclofenac sodium - a gastroretentive controlled delivery system. Pak J Pharm Sci, 2008, 21(4), 451-454.
130. Badve, S.S.; Sher, P.; Korde, A.; Pawar, A.P. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm, 2007, 65(1), 85-93.
131. Sher, P.; Ingavle, G.; Ponrathnam, S.; Benson, J.; Li, N.H.; Pawar, A. Novel/conceptual floating pulsatile system using high internal phase emulsion based porous material intended for chronotherapy. AAPS PharmSciTech, 2009, 10(4), 1368-1380.
132. Sharma, S.; Pawar, A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm, 2006, 313(1-2), 150-158.
133. Peng, N.F.; Yang, L.; Chen, R.; Cai, X.; Li, L.; Li, Z.; Zhou, Q.; Zhou, J.; Jiang, Z. Synthesis of colon-specific prodrug of indomethacin and its inhibitory effect on liver metastasis from colon cancer. Zhonghua Zhong Liu Za Zhi, 2010, 32(3), 164-168.
134. Terdiman, J.P.; Johnson, L.K.; Kim, Y.S.; Sleisenger, M.H.; Gum, J.R.; Hayes, A.; Weinberg, V.K.; McQuaid, K.R. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci, 2009, 54(11), 2488-2496.
135. Basit, A.W. Advances in colonic drug delivery. Drugs, 2005, 65(14), 1991-2007.
136. Singh, B.N. Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv Formul, 2007, 1(1), 53-63.
137. Fadda, H.M.; Basit, A.W. Dissolution of pH responsive formulations in media resembling intestinal fluids: bicarbonate versus phosphate buffers. J Drug Del Sci Tech,. 2005, 15, 273-279.
138. Wei, H.; Li-Fang, F.; Bai, X.; Chun-Lei, L.; Qing, D.; Yong-Zhen, C.; De-Ying, C. An investigation into the characteristics of chitosan/Kollicoat SR30D free films for colonic drug delivery. Eur J Pharm Biopharm, 2009, 72(1), 266-274.
139. Luppi, B.; Cerchiara, T.; Bigucci, F.; Orienti, I.; Zecchi; V. pHsensitive polymeric physical-mixture for possible site-specific delivery of ibuprofen. Eur J Pharm Biopharm, 2003, 55(2), 199-202.
140. Cheng, G.; An, F.; Zou, M.J.; Sun, J.; Hao, X.H.; He, Y.X. Timeand pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol, 2004, 10(12), 1769-1774.
141. Talukder, R.M.; Fassihi, R. Development and in-vitro evaluation of a colon-specific controlled release drug delivery system. J Pharm Pharmacol, 2008, 60(10), 1297-1303.
142. Chuong, M.C.; Christensen, J.M.; Ayres, J.W. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis. Pharm Dev Technol, 2009, 14(1), 116-125.
143. Makhlof, A.; Tozuka, Y.; Takeuchi, H. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm, 2009, 72(1), 1-8.
144. Patel, M.M., Shah, T.J.; Amin, A.F. Design, development and optimization of a novel time and pH-dependent colon targeted drug delivery system. Pharm Dev Technol, 2009, 14(1): p. 62-9.
145. Nunthanid, J.; Luangtana-anan, M.; Sriamornsak, P.; Limmatvapirat, S.; Huanbutta, K.; Puppipipatkhachorn, S. Use of spray-dried chitosan acetate and ethylcellulose as compression coats for colonic drug delivery: effect of swelling on triggering in vitro drug release. Eur J Pharm Biopharm, 2009, 71(2), 356-361.
146. Ji, C.M.; Xu, H.N.; Wu, W. Guar gum as potential film coating material for colon-specific delivery of fluorouracil. J Biomater Appl, 2009, 23(4), 311-329.
147. Chandran, S.; Sanjay, K.S.; Ali Asghar, L.F. Microspheres with pH modulated release: design and characterization of formulation variables for colonic delivery. J Microencapsul, 2009, 26(5), 420-431.
148. Asghar, L.F.; Chure, C.B.; Chandran, S. Colon specific delivery of indomethacin: effect of incorporating pH sensitive polymers in xanthan gum matrix bases. AAPS Pharm Sci Tech, 2009, 10(2), 418-429.
149. Yehia, S.A., Elshafeey, A.H.; Sayed, I.; Shehata, A.H. Optimization of budesonide compression-coated tablets for colonic delivery. AAPS Pharm Sci Tech, 2009, 10(1), 147-157.
150. Ali Asghar, L.F.; Azeemuddin, Md.; Jain, V.; Chandran, S. Design and in vitro evaluation of formulations with pH and transit time controlled sigmoidal release profile for colon-specific delivery. Drug Deliv, 2009, 16 (6), 295-303.
151. Karrout, Y.; Neut, C.; Wils, D.; Siepmann, F.; Deremaux, L.; Flament, M.P.; Dubreuil, L.; Desreumaux, P.; Siepmann, J. Novel polymeric film coatings for colon targeting: Drug release from coated pellets. Eur J Pharm Sci, 2009, 37(3-4), 427-433.
152. Liu, H., Yang, X.G.; Nie, S.F.; Wei, L.L.; Zhou, L.L.; Liu, H.; Tang, R.; Pan, W.S. Chitosan-based controlled porosity osmoticpump for colon-specific delivery system: screening of formulation variables and in vitro investigation. Int J Pharm, 2007, 332(1-2), 115-124.
153. El-Kamel, A.H.; Abdel-Aziz, A.A.M.; Fatani, A.J.; El-Subbagh, H.I. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment. Int J Pharm, 2008, 358(1-2), 248-255.
154. Ruiz, J.F.; Radics, G.; Windle, H.; Serra, H.O.; Simplício, A.L.; Kedziora, K.; Fallon, P.G.; Kelleher, D.P.; Gilmer, J.F. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease. J Med Chem, 2009, 52(10), 3205-3211.
155. Kong, H.; Lee, Y.; Hong, S.; Han, J.; Choi, B.; Jung, Y.; Kim, Y.M. Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J Drug Target, 2009, 17(6), 450-458.
156. Cassano, R.; Trombino, S.; Cilea, A.; Ferrarelli, T.; Muzzalupo, R.; Picci, N. L-lysine pro-prodrug containing trans-ferulic acid for 5- amino salicylic acid colon delivery: synthesis, characterization and in vitro antioxidant activity evaluation. Chem Pharm Bull (Tokyo), 2010, 58(1), 103-105.
157. Dhaneshwar, S.S.; Gairola, N.; Kandpal, M.; Vadmerkar, G.; Bhatt, L.; Rathi, B.; Kadam, S.S. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5- aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. Eur J Med Chem, 2009, 44(10), 3922-3929.
158. Zou, M.J.; Cheng, G.; Okamoto, H.; Hao, X.M.; An, F.; Cui, F. D.; Danjo, K. Colon-specific drug delivery systems based on cyclodextrin prodrugs: in vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol, 2005, 11(47), 7457-7460.
159. Joo, K.; Lee, Y.; Choi, D.; Han, J., Hong, S.; Kim, Y.M.; Jung, Y. An anti-inflammatory mechanism of taurine conjugated 5- aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1betamediated NFkappaB activation. Eur J Pharmacol, 2009, 618(1-3), 91-97.
160. Maestrelli, F.; Zerrouk, N.; Cirri, M.; Mennini, N.; Mura, P. Microspheres for colonic delivery of ketoprofen-hydroxypropylbeta-cyclodextrin complex Eur J Pharm Sci, 2008, 34(1), 1-11.